scholarly journals Associations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus

2015 ◽  
Vol 3 (2) ◽  
pp. 77-85 ◽  
Author(s):  
Akihiko Sato ◽  
Akiomi Yoshihisa ◽  
Yuki Kanno ◽  
Mai Takiguchi ◽  
Shunsuke Miura ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Heart Failure Patients ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Patients With Diabetes

scholarly journals Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis

2021 ◽  
Vol 12 ◽  
pp. 204201882199648
Author(s):  
Rimesh Pal ◽  
Mainak Banerjee ◽  
Soham Mukherjee ◽  
Ranjitpal Singh Bhogal ◽  
Amanpreet Kaur ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Subgroup Analysis ◽  
Observational Studies ◽  
Meta Analysis ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Patients With Diabetes ◽  
Hospital Use

Background: Few observational studies have shown a beneficial effect of dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with coronavirus disease 2019 (COVID-19), although results are not consistent. The present systematic review and meta-analysis was undertaken to provide a precise summary of the effect of DPP4i use (preadmission or in-hospital) and mortality in COVID-19 patients with diabetes mellitus (DM). Methods: PubMed and Google Scholar databases were systematically searched using appropriate keywords to 4 January 2021, to identify observational studies reporting mortality in COVID-19 patients with DM using DPP4i versus those not using DPP4i. Preadmission and in-hospital use of DPP4i were considered. Study quality was assessed using the Newcastle–Ottawa Scale. Unadjusted and adjusted pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated. Subgroup analysis was performed for studies reporting preadmission and in-hospital use of DPP4i. Results: We identified nine observational studies of high quality pooling data retrieved from 7008 COVID-19 patients with DM. The pooled analysis of unadjusted and adjusted data did not show any significant association between DPP4i use and mortality in COVID-19 patients with DM. However, on subgroup analysis, we found that in-hospital (and not preadmission) DPP4i use was associated with reduced mortality (unadjusted OR 0.37, 95% CI 0.23, 0.58, p < 0.0001, I2 = 0% and adjusted OR 0.27, 95% CI 0.13, 0.55, p = 0.0003, I2 = 12%). Conclusions: In-hospital use of DPP4i is associated with a significant reduction in COVID-19 mortality. Hence, it would be prudent to initiate or continue DPP4i in COVID-19 patients with DM if not contraindicated.

scholarly journals Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus

2021 ◽  
pp. 1-10
Author(s):  
Takeshi Hasegawa ◽  
Junhui Zhao ◽  
Brian Bieber ◽  
Jarcy Zee ◽  
Ronald L. Pisoni ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Iron Deficiency ◽  
Interaction Analysis ◽  
Conditional Logistic Regression ◽  
Resistance Index ◽  
Dipeptidyl Peptidase ◽  
Repeated Measurements ◽  
Study Phase ◽  
Dipeptidyl Peptidase 4 ◽  
Patients With Diabetes

<b><i>Introduction:</i></b> Dipeptidyl peptidase-4 (DPP-4) has been hypothesized to improve responsiveness to erythropoiesis-stimulating agent (ESA). We aimed to describe the trend in DPP-4 inhibitor prescription patterns and assess the association between DPP-4 inhibitor prescription and ESA hyporesponsiveness (eHypo) in Japanese hemodialysis (HD) patients with diabetes mellitus (DM). <b><i>Methods:</i></b> We analyzed data from the Japan Dialysis Outcomes and Practice Patterns Study phase 4–6 (2009–2017) on patients with DM who underwent HD thrice per week for at least 4 months. The primary exposure of interest was having a DPP-4 inhibitor prescription. The primary analysis outcomes were a binary indicator of eHypo (mean hemoglobin &#x3c;10 and mean ESA dose &#x3e;6,000 units/week over 4 months) and the natural log-transformed ESA resistance index (ERI). We used conditional logistic regression to compare within-patient changes in eHypo before and after initial DPP-4 inhibitor prescription. We used linear generalized estimating equation models to compare continuous ERI outcomes while accounting for within-patient repeated measurements with an exchangeable correlation structure. <b><i>Results:</i></b> There was a monotonic increase in DPP-4 inhibitor prescription according to study year up to 20% in 2017. Moreover, 12.8% of patients with a DPP-4 inhibitor prescription were ESA hyporesponsive before the initial DPP-4 inhibitor prescription. After DPP-4 inhibitor prescription, the odds of eHypo and mean log-ERI remained unchanged in the whole cohort of our study. The interaction analysis of DPP-4 inhibitor and sideropenia showed that DPP-4 inhibitors attenuated eHypo in the patients without iron deficiency. <b><i>Conclusion:</i></b> Our findings indicate a recent increase in DPP-4 inhibitor prescription among Japanese HD patients with DM. DPP-4 inhibitors could improve ERI in patients undergoing HD without iron deficiency.

scholarly journals Effect of Carperitide on Plasma Adiponectin Levels in Acute Decompensated Heart Failure Patients With Diabetes Mellitus

2009 ◽  
Vol 73 (12) ◽  
pp. 2264-2269 ◽  
Author(s):  
Masayuki Yamaji ◽  
Takayoshi Tsutamoto ◽  
Toshinari Tanaka ◽  
Chiho Kawahara ◽  
Keizo Nishiyama ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Plasma Adiponectin ◽  
Heart Failure Patients ◽  
Patients With Diabetes
Sign in / Sign up

Export Citation Format

Share Document